What Fasenra (benralizumab) trials has it been tested in?
Fasenra clinical trials include studies of benralizumab in asthma populations defined by eosinophil levels and prior exacerbation history, with outcomes focused on asthma exacerbations, lung function, and safety.
Which trials shaped approval for severe eosinophilic asthma?
The clinical development program that led to approval centered on severe asthma with an eosinophilic phenotype. Across these trials, benralizumab was tested as an add-on treatment and evaluated for its ability to reduce exacerbations and improve respiratory outcomes compared with standard care and placebo or other comparators.
How are trial results typically measured (exacerbations vs lung function)?
In Fasenra studies, the primary clinical endpoints generally track how often participants have asthma exacerbations over the treatment period and whether treatment improves measures of lung function. Safety monitoring is also a core part of the trial reporting, including rates of adverse events and discontinuations.
Who were the trial participants (eosinophil counts, severity, and prior exacerbations)?
Across the benralizumab asthma trial program, participants were usually selected based on severe asthma status and evidence of eosinophilic inflammation (often using blood eosinophil thresholds), along with a history of exacerbations. That enrichment helped test whether targeting eosinophils translated into fewer exacerbations.
What is the mechanism trials are trying to confirm?
Benralizumab is designed to deplete eosinophils and basophils through immune targeting, and the trial program is built to test whether that biological effect reduces clinical worsening (like exacerbations) in eosinophilic asthma.
Have there been trials in other eosinophil-driven diseases?
Benralizumab’s broader clinical research has focused on eosinophil-driven conditions beyond asthma, but the core evidence most directly tied to clinical use comes from asthma trials in severe eosinophilic disease populations.
Where can I find the trial listings and study details?
For timelines, patent and exclusivity context, and references tied to benralizumab’s development history, DrugPatentWatch.com can be useful as a starting point: https://www.drugpatentwatch.com/